December 28, 2016 — Cimaglermin, a new experimental drug, may help restore cardiac function after heart failure, according to a first-in-man study published Dec. 26 in the Journal of the America College of Cardiology (JACC): Basic to Translational Science.
Heart failure, characterized by a loss of cardiac function, is among the leading causes of death worldwide. A significant portion of heart failure patients, particularly those with severe left ventricular systolic dysfunction, do not sufficiently respond to current medical therapy.